Close

This is a StreetInsider.com Premium Only Page

Please sign-up to enjoy all the benefits of StreetInsider.com Premium or log-in if you're already a member.

Send to a Friend Font Size: Increase Decrease

Back to IKT Stock Lookup

(IKT) – Business Wire

Feb 17, 2021 08:05 AM Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease and Related Disorders

Back to IKT Stock Lookup